Sorafenib-treated Th9 cells exhibit superior anti-tumor effect in lung metastasis



Summary

Sorafenib, a multi-kinase inhibitor, enhances the anti-tumor activity of Th9 cells (a type of T helper cell) in lung metastasis models. Specifically, sorafenib treatment increased Th9 cell proliferation, migration towards the lung, and IFN-γ production. In vivo studies showed that sorafenib-treated Th9 cells significantly reduced lung tumor burden compared to control Th9 cells. This enhanced anti-tumor effect is linked to improved trafficking to the lung and augmented IFN-γ secretion, highlighting sorafenib as a potential therapeutic strategy to boost the efficacy of Th9 cell-based immunotherapies for lung cancer.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!